amifampridine has been researched along with Lassitude in 6 studies
Amifampridine: 4-Aminopyridine derivative that acts as a POTASSIUM CHANNEL blocker to increase release of ACETYLCHOLINE from nerve terminals. It is used in the treatment of CONGENITAL MYASTHENIC SYNDROMES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thirteen subjects with amyotrophic lateral sclerosis and seven subjects with only a lower motor neuron syndrome." | 2.76 | Effects of 3-4 diaminopyridine (DAP) in motor neuron diseases. ( Bertorini, TE; Igarashi, M; Li, YD; Rashed, H; Tolley, EA; Zeno, M, 2011) |
| "2% of patients presented adverse drug reactions (ADRs) while using moderate doses of 3,4-DAP (20-30 mg daily or up to 80 mg daily for patients with LEMS) for periods of up to 51 months." | 2.75 | 3,4-diaminopyridine safety in clinical practice: an observational, retrospective cohort study. ( Allain, H; Edan, G; Flet, L; Guillard, O; Javaudin, L; Leray, E; Polard, E, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Flet, L | 1 |
| Polard, E | 1 |
| Guillard, O | 1 |
| Leray, E | 1 |
| Allain, H | 1 |
| Javaudin, L | 1 |
| Edan, G | 1 |
| Bertorini, TE | 1 |
| Rashed, H | 1 |
| Zeno, M | 1 |
| Tolley, EA | 1 |
| Igarashi, M | 1 |
| Li, YD | 1 |
| Mainero, C | 1 |
| Inghilleri, M | 1 |
| Pantano, P | 1 |
| Conte, A | 1 |
| Lenzi, D | 1 |
| Frasca, V | 1 |
| Bozzao, L | 1 |
| Pozzilli, C | 1 |
| Debouverie, M | 1 |
| Pittion, S | 1 |
| Boërio, D | 1 |
| Lefaucheur, JP | 1 |
| Hogrel, JY | 1 |
| Créange, A | 1 |
| Sheean, GL | 1 |
| Murray, NM | 1 |
| Rothwell, JC | 1 |
| Miller, DH | 1 |
| Thompson, AJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised, Double Blinded Cross-over Study Comparing the Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple Sclerosis[NCT01149525] | Phase 3 | 59 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for amifampridine and Lassitude
| Article | Year |
|---|---|
[Pathophysiology and treatment of fatigue in multiple sclerosis].
Topics: 4-Aminopyridine; Acute Disease; Amantadine; Amifampridine; Asthenia; Benzhydryl Compounds; Central N | 2006 |
3 trials available for amifampridine and Lassitude
| Article | Year |
|---|---|
3,4-diaminopyridine safety in clinical practice: an observational, retrospective cohort study.
Topics: 4-Aminopyridine; Adolescent; Adult; Aged; Amifampridine; Child; Cohort Studies; Dyskinesias; Fatigue | 2010 |
Effects of 3-4 diaminopyridine (DAP) in motor neuron diseases.
Topics: 4-Aminopyridine; Adult; Aged; Aged, 80 and over; Amifampridine; Cross-Over Studies; Double-Blind Met | 2011 |
Enhanced brain motor activity in patients with MS after a single dose of 3,4-diaminopyridine.
Topics: 4-Aminopyridine; Adult; Amifampridine; Axons; Cross-Over Studies; Double-Blind Method; Electromyogra | 2004 |
2 other studies available for amifampridine and Lassitude
| Article | Year |
|---|---|
[Fatigue and episodic exhaustion as a feature of multiple sclerosis].
Topics: 4-Aminopyridine; Amantadine; Amifampridine; Benzhydryl Compounds; Fatigue; Humans; Hypnotics and Sed | 2006 |
An open-labelled clinical and electrophysiological study of 3,4 diaminopyridine in the treatment of fatigue in multiple sclerosis.
Topics: 4-Aminopyridine; Adult; Amifampridine; Analysis of Variance; Case-Control Studies; Electromyography; | 1998 |